EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective

Akshay Badakere, Vibha Badrinath, Hennaav Kaur Dhillon, Abinaya Valliappan, Viswanathan Natarajan, Sumita Agarkar

Indian Journal of Ophthalmology · 2025

DOI: 10.4103/ijo.ijo_2198_23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Ophthalmology, 2025. Verfasst von Akshay Badakere und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Ophthalmology and Strabismus, Medical Research Foundation, Chennai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Esotropia, Botulinum Toxins, Type A, Oculomotor Muscles, Eye Movements. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To analyze the outcomes of botulinum toxin A injection in acute acquired comitant esotropia (AACE).

Methods

This is a retrospective study that included cases diagnosed as AACE between January 2022 and February 2023. Patients who were treated with Botox and completed a minimum 3 months follow-up were included in the study. All the patients underwent a complete ophthalmic, orthoptic examination and neuroimaging. The effects of age, onset of esotropia, screen time, deviation pre injection, mode of injection (transconjunctival/ open sky) and whether injection was administered in one/both eyes on successful outcome were analysed.

Results

Twenty-seven patients (20 male, seven female) were included in the study. The median age was 10 years. The median deviation for distance and near preinjection was 35 and 40 prism diopters, respectively. Complete resolution of symptoms was noted in 18 patients (66.6%). Four patients needed prisms, two required repeat injections, and one each needed surgery and divergence therapy. Six patients developed ptosis. None of the risk factors seemed to affect outcomes.

Conclusion

Botulinum toxin injected into the medial rectus is a safe and viable option for AACE. Preinjection counseling about ptosis, recurrence needing prisms, reinjection, or surgery is important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsotropiaBotulinum Toxins, Type AOculomotor MusclesEye MovementsVision, BinocularHumansMaleRetrospective StudiesFemaleNeuromuscular AgentsChildIndiaAcute DiseaseFollow-Up StudiesTreatment OutcomeAdolescentAdultInjections, IntramuscularChild, PreschoolYoung Adult

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Pediatric Ophthalmology and Strabismus, Medical Research Foundation, Chennai, Tamil Nadu, India.
  • Department of Biostatistics, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Zitieren

APA

Badakere, A., Badrinath, V., Dhillon, H. K., Valliappan, A., Natarajan, V., & Agarkar, S. (2025). Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_2198_23

Vancouver

Badakere A, Badrinath V, Dhillon HK, Valliappan A, Natarajan V, Agarkar S. Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective. Indian Journal of Ophthalmology. 2025. doi:10.4103/ijo.ijo_2198_23

BibTeX
@article{Badakere2025,
  author = {Badakere, Akshay and Badrinath, Vibha and Dhillon, Hennaav Kaur and Valliappan, Abinaya and Natarajan, Viswanathan and Agarkar, Sumita},
  title = {Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective},
  journal = {Indian Journal of Ophthalmology},
  year = {2025},
  doi = {10.4103/ijo.ijo_2198_23}
}
Kostenlos starten →